Clinical Trial Detail

NCT ID NCT01283945
Title Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Ethical Oncology Science
Indications

Advanced Solid Tumor

Therapies

Lucitanib

Age Groups: adult senior

No variant requirements are available.